Quality of Life in Patients With Inflammatory Bowel Disease: Importance of Psychological Symptoms

Maria-Andriani Mitropoulou 1, Evangelos C. Fradelos 2, Ka Y. Lee 3, Foteini Malli 1, Konstantinos Tsaras 1, Nikolaos G. Christodoulou 4, Ioanna V. Papathanasiou 1

1. Nursing, University of Thessaly, Larissa, GRC 2. Nursing, University of Thessaly, Larissa, GRC 3. Health Sciences, Mid Sweden University, Östersund, SWE 4. Psychiatry, University of Thessaly, Larissa, GRC

Corresponding author: Ioanna V. Papathanasiou, iopapathanasiou@yahoo.gr

Abstract

Background
Depressive, anxiety, and stress symptoms are prevalent in patients with inflammatory bowel disease (IBD) and may negatively influence the disease course and quality of life. The study aimed to assess the relationship between psychological factors and patients’ quality of life (QoL).

Materials and methods
A cross-sectional study with the use of a structured questionnaire among 38 patients with Crohn’s disease and 30 with ulcerative colitis was conducted. The inflammatory bowel disease questionnaire (IBDQ-32) was used to evaluate the patients’ quality of life, and the Depression, Anxiety, Stress Scale (DASS21) was used to evaluate these psychological factors. Pearson descriptive statistics and multiple regression analyses were performed.

Results
According to the findings of the multiple regression analysis, depressive, anxiety, and stress symptoms were negatively associated with quality of life. Participants with higher scores of anxiety had inferior QoL in intestinal symptoms (p=0.013) and in systemic symptoms (p=0.013), with higher scores of depression had inferior QoL in emotional function (p<0.001), and higher scores of stress had inferior QoL in the domain of social support (p=0.002). Psychological symptoms of emotional disorders appear to be associated with lower quality of life in IBD patients.

Conclusion
This study examined levels of depression, anxiety, and stress in Greek patients with IBD, which were associated with lower levels of their quality of life. Interventions to improve QoL in patients with IBD should consider the effect of psychological symptoms.

Introduction
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder of the gastrointestinal tract and is often accompanied by embarrassing bowel and systemic symptoms [3]. Recent studies have reported an increased risk for anxiety or depression in both children and adults with IBD [2]. Psychological factors have a special role in this disease as they can trigger the clinical appearance of the symptoms or modify IBD symptoms [3]. The bidirectional relationship between IBD and psychological problems can be explained in terms of the ‘brain-gut’ axis, meaning that the presence of anxiety and depressive symptoms or disorders can increase intestinal inflammation and may contribute to disease relapse, and, conversely, intestinal inflammation can negatively influence mood [4].

Quality of life (QoL) can be defined in many ways, making its measurement and incorporation into scientific study challenging. QoL is defined by the World Health Organization as “an individual’s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns” [5]. The symptoms of IBD have a negative impact on patients’ well-being and quality of life because dysfunctions usually affect daily activities, performance in school, ability to work, and social life [6]. Mental health is an important part of caring for these patients but is often overlooked.


**Literature Review**

IBD is a chronic inflammatory disease of the gastrointestinal tract and is divided into Crohn’s disease and ulcerative colitis. It occurs in genetically susceptible individuals after an exaggerated immune response to a normal stimulus such as intestinal flora [1]. The relapsing and remitting course and chronic nature of IBD mean that patients frequently deal with uncomfortable symptoms and side effects of medications used to treat these symptoms, which can lead to lower quality of life (QoL) [7]. Several factors have been identified that influence QoL in IBD, including disease activity, psychological status, fatigue, illness perceptions, coping strategies, and social support. Health-related quality of life is a multidimensional measure that reflects the impact of IBD on an individual’s physical, psychological and social functioning [8].

According to the results of a systematic review, individuals with IBD have higher rates of both anxiety and depression symptoms compared with healthy individuals without IBD [9]. There is an increased incidence of psychiatric disorders, mainly depressive and anxiety disorders, after the diagnosis of IBD [9, 10]. Previous research has highlighted that stress and depression are higher during active illness compared to inactive illness and quality of life scores appear lower, particularly during an event [11]. A meta-analysis referring to the evaluation of patients living with IBD showed the adverse effect of the disease on QoL [12]. The symptoms of IBD disrupt interpersonal relationships, daily activities, social participation, and mental well-being, affecting the QoL of both patients and their caregivers [12].

Overall, the psychological difficulties, such as depression, anxiety, stress, and social isolation, experienced by IBD patients seem to be associated with lower QoL. Studying this association may improve care for patients with IBD. The present study aimed to assess the relationship between QoL and psychological symptoms.

**Materials And Methods**

**Study Design**

A cross-sectional study using a structured questionnaire (IBDQ-32) was conducted. The convenience sample consisted of IBD patients in Greece. The questionnaire was offered online to members of the official association of people with Crohn’s disease and ulcerative colitis in Greece - Hellenic Society of Crohn’s Disease and Ulcerative Colitis Patients (HELLESCC). Data collection lasted from March 2021 to July 2021. The online method of administration was necessary due to the Covid-19 pandemic and in order for the sample to represent as many different regions of Greece as possible. The sample consisted of 68 patients that agreed to participate in the current study and successfully answered all the questions of the questionnaire. Of the 68 patients, 38 (55.88%) are diagnosed with Crohn’s disease, and 30 (44.12%) have ulcerative colitis. The inclusion criteria were the following: consent to participate in the study, 18 or more years of age, ability to communicate in the Greek language, and an official diagnosis of IBD.

**Ethics**

This study was conducted in compliance with the ethical standards. The study protocol was approved by the institutional review board (IRB) of the official association of people with Crohn’s Disease and Ulcerative Colitis in Greece, HELLESCC (IRB approval No:021/26.03.2021). The study adheres to the Declaration of Helsinki, and informed consent was obtained from participants. In addition, licenses for the questionnaires were issued from the respective researchers.

**Study Measures**

The Inflammatory Bowel Disease Questionnaire 32 (IBDQ-32) and the Depression, Anxiety, and Stress Scale-21 (DASS-21) were used in the current study. The Inflammatory Bowel Disease Questionnaire 32 (IBDQ-32) is one of the most commonly used measures to assess IBD patients’ QoL. IBDQ-32 is a 32-item questionnaire that includes four aspects of the patient’s life: intestinal symptoms (10 items), systemic symptoms (five items), social (12 items), and emotional domains (five items). The answers are on the Likert scale from 1 (worst case) to 7 (best case), which indicates how much the statement applied to them during the last two weeks, with lower scores reflecting worse QoL. The questionnaire was translated and validated in Greek by Pallis et al., and Cronbach’s alpha (~0.78) has been tested for validity and reliability [13]. The Depression, Anxiety and Stress Scale-21 (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains seven items, divided into subscales with similar content. Participants answer on a four-point Likert scale (0 = did not apply to me at all, 3 = it was too much for me, or most of the time) which indicates how much the statement applied to them during the previous week. Scores for depression, anxiety, and stress are calculated by summing the scores for the relevant items. The questionnaire was translated and validated for the Greek population by Lyrakos et al., and Cronbach’s alpha of the scale was α=0.965, which suggests that the Greek translation of the DASS-21 is both reliable and valid [14]. A series of demographic and clinical characteristics such as age, gender, and marital status were also recorded.
Statistical Analysis

Mean, standard deviation (SD), median, and interquartile range were used to describe the quantitative variables. Absolute (N) and relative (%) frequencies were used to describe the categorical variables. The Student’s t-test or the non-parametric Mann-Whitney criterion was used to compare quantitative variables between two groups. The parametric analysis of dispersion analysis (ANOVA) or the non-parametric Kruskal-Wallis criterion was used to compare quantitative variables between more than two groups. To reduce the type I error due to multiple comparisons, Bonferroni correction was used, according to which the significance level is 0.05/k (k = number of comparisons). To correlate the relationship between two quantitative variables, Pearson or Spearman correlation tests were used. The correlation is considered low when the correlation coefficient (r) ranges from 0.1 to 0.3, moderate when the correlation coefficient ranges from 0.31 to 0.5, and high when the coefficient is greater than 0.5. Linear regression analysis with stepwise integration was used to find independent factors related to DASS-21 and IBDQ, from which dependencies (b) and their standard errors (SE) were derived. The linear regression analysis, where necessary, was performed using logarithmic transformations. The significance levels are bilateral, and the statistical significance was set at 0.05. The statistical program SPSS version 22.0 (IBM Inc., Armonk, New York) was used for the analysis.

Results

The study population included 68 patients whose demographic and clinical characteristics are presented in Table 1.
### TABLE 1: Demographic and clinical characteristics of the participants (n=68)

|                                | Crohn’s disease | Ulcerative colitis |
|--------------------------------|-----------------|--------------------|
| **Suffer from**                |                 |                    |
| Crohn’s disease                | 38              | 55.9               |
| Ulcerative colitis             | 30              | 44.1               |
| **Age of first diagnosis of IBD in years, mean (SD)** |                 |                    |
|                                | 28.5 (13.3)     |                    |
| **Family members who suffer from IBD** |                 |                    |
| No                             | 54              | 79.4               |
| Yes                            | 14              | 20.6               |
| **The disease is active in the current period** |                 |                    |
| No                             | 47              | 69.1               |
| Yes                            | 21              | 30.9               |
| **Have you ever been hospitalized for this disease?** |                 |                    |
| No                             | 23              | 34.3               |
| Yes                            | 44              | 65.7               |
| **How many times in total have you been hospitalized because of this disease? SD, median** |                 |                    |
|                                | 2.6 (5.5)       | 1 (0-3)            |
| **Have you had any surgery related to this disease** |                 |                    |
| No                             | 59              | 86.8               |
| Yes                            | 9               | 13.2               |
| **Do you suffer from another serious disease?** |                 |                    |
| No                             | 58              | 85.3               |
| Yes                            | 10              | 14.7               |
| Anemia                         | 1               | 1.5                |
| Asthma                         | 1               | 1.5                |
| Hard of hearing                | 1               | 1.5                |
| Idiopathic thrombocytosis      | 1               | 1.5                |
| Osteoporosis                   | 1               | 1.5                |
| Diabetes                       | 1               | 1.5                |
| Multiple sclerosis             | 1               | 1.5                |
| Systemic lupus erythematosus   | 1               | 1.5                |
| Hypothyroidism, vitiligo, psoriasis, psoriatic arthritis | 1 | 1.5 |
| Hashimoto’s disease            | 1               | 1.5                |

All participants were Greek. Of them, 66.2% were women, and the mean age was 39.3 years (SD = 13.5 years). Concerning the clinical characteristics, a total of 55.9% of participants suffered from Crohn’s disease and 44.1% from ulcerative colitis. The mean age at the first diagnosis of IBD was 28.5 years (SD = 13.3 years), with 20.6% of participants having someone in their family who suffered from IBD and 30.9% having active disease at the time of the study. In addition, 65.7% of the participants had been hospitalized at least once due to the disease, 13.2% had undergone surgery related to the specific disease, while 14.7% had another significant disease.

The descriptive results for the scores on the dimensions of the scale of anxiety, depression, and stress are presented in Table 2.

2022 Mitropoulou et al. Cureus 14(8): e28502. DOI 10.7759/cureus.28502
The scores range from 0 to 42 points with a higher score indicating higher levels of anxiety, depression, and stress. The average score for depression was 14.3 points (SD = 11.5 points), for anxiety was 11.1 points (SD = 10.1 points), and for stress was 18.5 points (SD = 11.5 points).

The descriptive results for the scores in the Greek version of IBDQ are presented in Table 3.

Higher scores indicate an increased quality of life. The score for intestinal symptoms ranged from 24 to 70 points, with the average value being 55.2 points (SD = 11.4 points), and the score for systemic symptoms ranged from 11 up to 35 points, with the average value being 23.8 points (SD = 5.9 units). Also, the score for emotional function ranged from 26 to 76 points, with the average value being 56.2 points (SD = 13.7 points), and for social activity, it ranged from 13 to 35 points, with the average value being 29.5 units (SD = 6.2 units).

The multiple linear regressions were performed, where the IBDQ-32 dimensions of ‘intestinal symptoms’, ‘systemic symptoms’, ‘emotional function’, and ‘social activity’ were used as dependent variables, and the demographic-clinical data and the scores of anxiety, depression, and stress were used as independent variables. The analyses were performed by the bidirectional stepwise regression, which is a combination of the forward and backward methods, testing at each step for variables to be included or excluded and by the use of logarithmic transformations.

Anxiety symptoms were independently associated with intestinal and systemic symptoms, depressive symptoms with emotional function, and stress symptoms with social function, domains of quality of life in IBD patients. In addition, the activity of disease was independently associated with intestinal, systemic symptoms, and social function (Table 4).
TABLE 4: Multiple linear regression (stepwise) with dependent and independent variables

|                                | β*   | SE** | p-value |
|--------------------------------|------|------|---------|
| **Intestinal symptoms of IBDQ-32 and anxiety** |      |      |         |
| Anxiety                        | -0.004 | 0.001 | 0.001  |
| The disease is active in the current period | No |      |         |
|                                | Yes | -0.057 | 0.024 | 0.019  |
| **Systemic symptoms of IBDQ-32 and anxiety** |      |      |         |
| Anxiety                        | -0.004 | 0.002 | 0.013  |
| Live alone                     | No |      |         |
|                                | Yes | 0.058  | 0.029 | 0.045  |
| **Emotional symptoms of IBDQ-32 and depression** |      |      |         |
| Depression                     | -0.005 | 0.001 | <0.001 |
| The disease is active in the current period | No |      |         |
|                                | Yes | -0.076 | 0.026 | 0.005  |
| **Social function of IBDQ-32 and stress** |      |      |         |
| Stress                         | -0.003 | 0.001 | 0.002  |
| The disease is active the current period | No |      |         |
|                                | Yes | -0.08  | 0.025 | 0.002  |

**Discussion**

The aim of this study was to investigate the levels of depression, anxiety, stress, and quality of life of patients with inflammatory bowel disease (IBD) and to examine possible correlations between the aforementioned variables. Anxiety and depression are the most common psychological disorders in patients with IBD, and patients’ self-reports of anxiety and depression are considered critical to the care of these patients [15, 16]. In addition, a population-based study reported that the prevalence of anxiety and depression during the lifetime of patients with IBD was 24.4-31.9% and 21.8-22.5%, respectively [17]. This study found patients with IBD reported higher levels of depression and stress compared to anxiety.

IBD has a significant impact on quality of life. A French cohort showed that half of IBD patients report poor quality of life and severe fatigue [18]. The symptoms of the disease disrupt interpersonal relationships, daily activities, social participation, and mental well-being, affecting the quality of life of both sufferers and their caregivers [19]. For these reasons, the assessment of the quality of life in patients with IBD is increasingly recognized by the medical and scientific community. Investigating the dimensions of patients’ quality of life, the data showed that this Greek sample reports a good quality of life in terms of emotional function (56.2±13.7). These results are not very different from the results of a previous study that assessed health-related QoL of eighty-nine IBD patients in South-Western Greece and in which the score of emotional function was 67 for participants with Crohn’s disease and 68 for patients with ulcerative colitis [20].

In this study, IBD patients with symptoms of anxiety were predisposed to have decreased quality of life in the domains of intestinal and systemic symptoms. The chronic nature and severity of symptoms cause stress and anxiety in patients, which were associated with lower quality of life [21]. Symptom-related concerns such as anxiety about losing bowel control, fatigue, fear of sexual dysfunction, social isolation, anxiety about not being able to function, fear of stigma, and feeling unclean are associated with levels of psychological distress [22]. In addition, results showed that the higher the participants’ depression levels, the lower their quality of life was in terms of their emotional function. Studies describe a two-way relationship between psychological problems and inflammatory activity. A previous bad psychological status...
may contribute to IBD symptoms, and, in turn, inflammatory activity is associated with the development of psychological disorders [23]. Depression is associated with a reduced response to treatment and periods of flare-ups [24]. Therefore, it is important to simultaneously look after emotional and physical well-being in order to ensure a good clinical course of the disease. In a recent study in which 70 patients diagnosed with IBD participated, it was found that positive psychological factors, such as body acceptance and meaning in life, are significant predictors of QoL [25]. Furthermore, a study conducted on 172 patients with IBD found that the disease severity index that predicts disease severity in IBD patients was significantly higher in patients with symptoms of moderate-severe stress, depression, anxiety, and impaired QoL [26].

Also, increased self-reported levels of stress were associated with decreased quality of life in areas of social activity. Physical symptoms often have an inhibitory effect on a person’s social activities, which is associated with increased stress. Similarly, the ability to work and participate in social activities is affected by high levels of psychological distress and leads to lifestyle changes and disturbances in social relationships and family life [22]. Studies show that the main factors that affect the quality of life of patients, both adults and children, are the presence of the symptoms, the severity of the disease, and emotional disorders [27, 28]. In this study, we found that participants with active disease had inferior QoL in intestinal symptoms, emotional function, and social support.

IBD patients’ quality of life and their mental status are also receiving attention. Screening patients with IBD for mood disorders has recently been shown to provide mental health benefits [11]. The effects of an untreated mental illness can be devastating and can worsen the disease course of IBD [22]. So, it is important to timely recognize mental disorders in the IBD population.

Limitations

The current study contains several limitations, including a small sample size. Collecting data online could lead to sampling bias. In addition, this study relied on self-reported data regarding patients’ diagnoses. Finally, this is a cross-sectional study in which no causal relationship can be tested. Therefore, future longitudinal studies including both adults and children are warranted.

Conclusions

This study delineated the impact of symptoms of anxiety, depression, and stress on a Greek IBD population. Emotional difficulties experienced by patients affect the biological, psychological, and social areas of their lives. Our findings emphasize the importance of a holistic approach and treatment of chronic IBD diseases. These patients should have timely access to multidisciplinary care, including mental health professionals, to control and manage psychological distress.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. IRB of the official association of people with Crohn’s Disease and Ulcerative Colitis in Greece issued approval 021/26.03.2021. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

The authors wish to thank all the patients with IBD who participated in this study.

References

1. McDowell C, Farooq U, Haseeb M: Inflammatory bowel disease. StatPearls Publishing, Treasure Island, FL; 2022.
2. de Souza HS, Fiocchi C, Iliopoulos D: The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017, 14:739-49. 10.1038/nrgastro.2017.110
3. Nurmi E, Haapamäki J, Pauvainens E, Rantanen A, Hillilä M, Arkkila P: The burden of inflammatory bowel disease on health care utilization and quality of life. Scand J Gastroenterol. 2015, 48:51-7. 10.3109/00365521.2012.685750
4. Bonaz BL, Bernstein CN: Brain-gut interactions in inflammatory bowel disease . Gastroenterology. 2015, 144:56-49. 10.1053/j.gastro.2012.10.003
5. WHOQOL - measuring quality of life . (2022). Accessed: March 11 2022: https://www.who.int/tools/whoqol
7. Benjamin J, Makhlaria GK, Kalaiavani M, Joshi YK: Nutritional status of patients with Crohn’s disease. Indian J Gastroenterol. 2008, 27:195-200.

8. Benchimol EI, Bernstein CN, Bitton A, et al.: The impact of inflammatory bowel disease in Canada 2018: a scientific report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn’s and Colitis Canada. J Can Assoc Gastroenterol. 2019, 2:51-5. 10.1097/jcag.000000000000052

9. Mikoecka-Walas A, Knowles SR, Keefer L, Graff L: Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis. 2016, 22:752-62. 10.1097/MIB.0000000000000620

10. Bennsbrook Evertz T, Thijsseens NA, Stokkers PC, Grootenhuis MA, Bockting CL, Nieuwkerk PT, Sprangers MA: Do inflammatory bowel disease patients with anxiety and depressive symptoms receive the care they need? J Crohns Colitis. 2012, 6:68-76. 10.1016/j.crohns.2011.07.006

11. Leone D, Gilardi D, Corrà BE, et al.: Psychological characteristics of inflammatory bowel disease patients: a comparison between active and nonactive patients. Inflamm Bowel Dis. 2019, 25:1399-407. 10.1095/ibd.liz400

12. Huppertz-Hauss G, Hevik ML, Langholz E, et al.: Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis. Inflamm Bowel Dis. 2015, 21:537-44. 10.1097/MIB.0000000000000272

13. Pallis AG, Vlachonikolis IG, Mouzas IA: Quality of life of Greek patients with inflammatory bowel disease. Validation of the Greek translation of the inflammatory bowel disease questionnaire. Digestion. 2001, 63:240-6. 10.1159/000051896

14. Lyarakos G, Arvaniti C, Smyrnioti M, Kontopanagioutou G: Translation and validation study of the depression anxiety stress scale in the greek general population and in a psychiatric patient’s sample. Eur Psychiatry. 2011, 26:1731. 10.1016/j.eurpsy.2011.09.017

15. Parekh KN, Shah S, McMaster K, et al.: Effects of caregiver burden on quality of life and coping strategies utilized by caregivers of adult patients with inflammatory bowel disease. Ann Gastroenterol. 2017, 30:89-95. 10.20524/agi.2016.0084

16. Gray WN, Graef DM, Schuman SS, Janicke DM, Hommel KA: Parenting stress in pediatric IBD: relations with child psychopathology, family functioning, and disease severity. J Dev Behav Pediatr. 2013, 34:237-44. 10.1097/DBP.0b013e318286558a

17. Marrie RA, Walker JR, Graff LA, et al.: Performance of administrative case definitions for depression and anxiety in inflammatory bowel disease. J Psychiatr Res. 2016, 89:107-15. 10.1016/j.jpsychires.2016.08.014

18. Willett N, Sarter H, Gower-Rousseau C, et al.: Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients. J Crohns Colitis. 2017, 11:165-74. 10.1093/ecocjc/jix145

19. Raimundo K, Montagut RT, Flores N, Low J: P196 the impact of inflammatory bowel disease severity on health-related quality of life. Inflamm Bowel Dis. 2018, 24:77. 10.1093/ibd/eyx038.035

20. Kalafateli M, Triantos C, Theocharis G, et al.: Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. Ann Gastroenterol. 2013, 26:243-8.

21. Tian T, Wang Z, Zhang J: Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies. Oxid Med Cell Longev. 2017, 2017:4555194. 10.1159/2017/4555194

22. Kiebles JL, Doerfler B, Keefer L.: Preliminary evidence supporting a framework of psychological adjustment to inflammatory bowel disease. Inflamm Bowel Dis. 2010, 16:1685-95. 10.1002/ibd.21215

23. Lix LM, Graff LA, Walker JR, et al.: Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis. 2008, 14:1573-84. 10.1002/ibd.20511

24. Häuser W, Janke KH, Klump B, Hinz A: Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm Bowel Dis. 2011, 17:421-32. 10.1002/ibd.21546

25. Matos R, Lencastre L, Rocha V, et al.: Quality of life in patients with inflammatory bowel disease: the role of positive psychological factors. Health Psychol Behav Med. 2021, 9:989-1005. 10.1080/21642850.2021.2007098

26. Swaminathan A, Fan D, Borichovsky GM, et al.: The disease severity index for inflammatory bowel disease is associated with psychological symptoms and quality of life, and predicts a more complicated disease course. Am J Gastroenterol. 2022, 56:664-74. 10.1111/ajg.17058

27. Bernhlev T, Jahnssen L, Lygren I, Henriksen M, Vann M, Moum B: Health-related quality of life in patients with inflammatory bowel disease measured with the short form-56: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis. 2005, 11:909-18. 10.1097/01.mib.0000179467.03748.99

28. Choulilaras G, Margoni D, Dimakou K, Fessatou S, Panayiotou I, Roma-Giannikou E: Disease impact on the quality of life of children with inflammatory bowel disease. World J Gastroenterol. 2017, 23:1067-75. 10.3748/wjg.v23.i16.1067